

World Journal of *Clinical Cases*

World J Clin Cases 2022 August 6; 10(22): 7620-8056



Contents

Thrice Monthly Volume 10 Number 22 August 6, 2022

OPINION REVIEW

- 7620 Whipple's operation with a modified centralization concept: A model in low-volume Caribbean centers
Cawich SO, Pearce NW, Naraynsingh V, Shukla P, Deshpande RR

REVIEW

- 7631 Role of micronutrients in Alzheimer's disease: Review of available evidence
Fei HX, Qian CF, Wu XM, Wei YH, Huang JY, Wei LH

MINIREVIEWS

- 7642 Application of imaging techniques in pancreaticobiliary maljunction
Wang JY, Mu PY, Xu YK, Bai YY, Shen DH
- 7653 Update on gut microbiota in gastrointestinal diseases
Nishida A, Nishino K, Ohno M, Sakai K, Owaki Y, Noda Y, Imaeda H
- 7665 Vascular complications of pancreatitis
Kalas MA, Leon M, Chavez LO, Canalizo E, Surani S

ORIGINAL ARTICLE

Clinical and Translational Research

- 7674 Network pharmacology and molecular docking reveal zedoary turmeric-trisomes in Inflammatory bowel disease with intestinal fibrosis
Zheng L, Ji YY, Dai YC, Wen XL, Wu SC

Case Control Study

- 7686 Comprehensive proteomic signature and identification of CDKN2A as a promising prognostic biomarker and therapeutic target of colorectal cancer
Wang QQ, Zhou YC, Zhou Ge YJ, Qin G, Yin TF, Zhao DY, Tan C, Yao SK

Retrospective Cohort Study

- 7698 Is anoplasty superior to scar revision surgery for post-hemorrhoidectomy anal stenosis? Six years of experience
Weng YT, Chu KJ, Lin KH, Chang CK, Kang JC, Chen CY, Hu JM, Pu TW

Retrospective Study

- 7708 Short- (30-90 days) and mid-term (1-3 years) outcomes and prognostic factors of patients with esophageal cancer undergoing surgical treatments
Shi MK, Mei YQ, Shi JL

- 7720** Effectiveness of pulsed radiofrequency on the medial cervical branches for cervical facet joint pain
Chang MC, Yang S
- 7728** Clinical performance evaluation of O-Ring Halcyon Linac: A real-world study
Wang GY, Zhu QZ, Zhu HL, Jiang LJ, Zhao N, Liu ZK, Zhang FQ
- 7738** Correlation between the warning symptoms and prognosis of cardiac arrest
Zheng K, Bai Y, Zhai QR, Du LF, Ge HX, Wang GX, Ma QB
- 7749** Serum ferritin levels in children with attention deficit hyperactivity disorder and tic disorder
Tang CY, Wen F
- 7760** Application of metagenomic next-generation sequencing in the diagnosis of infectious diseases of the central nervous system after empirical treatment
Chen YY, Guo Y, Xue XH, Pang F
- 7772** Prognostic role of multiple abnormal genes in non-small-cell lung cancer
Yan LD, Yang L, Li N, Wang M, Zhang YH, Zhou W, Yu ZQ, Peng XC, Cai J
- 7785** Prospective single-center feasible study of innovative autorelease bile duct supporter to delay adverse events after endoscopic papillectomy
Liu SZ, Chai NL, Li HK, Feng XX, Zhai YQ, Wang NJ, Gao Y, Gao F, Wang SS, Linghu EQ

Clinical Trials Study

- 7794** Performance of Dexcom G5 and FreeStyle Libre sensors tested simultaneously in people with type 1 or 2 diabetes and advanced chronic kidney disease
Ólafsdóttir AF, Andelin M, Saeed A, Sofizadeh S, Hamoodi H, Jansson PA, Lind M

Observational Study

- 7808** Complications of chronic pancreatitis prior to and following surgical treatment: A proposal for classification
Murruste M, Kirsimägi Ü, Kase K, Veršinina T, Talving P, Lepner U
- 7825** Effects of comprehensive nursing on postoperative complications, mental status and quality of life in patients with glioma
Dong H, Zhang XL, Deng CX, Luo B

Prospective Study

- 7832** Predictors of long-term anxiety and depression in discharged COVID-19 patients: A follow-up study
Boyraz RK, Şahan E, Boylu ME, Kırpınar İ

META-ANALYSIS

- 7844** Same-day single-dose vs large-volume split-dose regimens of polyethylene glycol for bowel preparation: A systematic review and meta-analysis
Pan H, Zheng XL, Fang CY, Liu LZ, Chen JS, Wang C, Chen YD, Huang JM, Zhou YS, He LP

- 7859** Rectal nonsteroidal anti-inflammatory drugs, glyceryl trinitrate, or combinations for prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: A network meta-analysis

Shi QQ, Huang GX, Li W, Yang JR, Ning XY

- 7872** Effect of celecoxib on improving depression: A systematic review and meta-analysis

Wang Z, Wu Q, Wang Q

CASE REPORT

- 7883** Rectal mature teratoma: A case report

Liu JL, Sun PL

- 7890** Antibiotic and glucocorticoid-induced recapitulated hematological remission in acute myeloid leukemia: A case report and review of literature

Sun XY, Yang XD, Yang XQ, Ju B, Xiu NN, Xu J, Zhao XC

- 7899** Non-secretory multiple myeloma expressed as multiple extramedullary plasmacytoma with an endobronchial lesion mimicking metastatic cancer: A case report

Lee SB, Park CY, Lee HJ, Hong R, Kim WS, Park SG

- 7906** Latamoxef-induced severe thrombocytopenia during the treatment of pulmonary infection: A case report

Zhang RY, Zhang JJ, Li JM, Xu YY, Xu YH, Cai XJ

- 7913** Multicentric reticulohistiocytosis with prominent skin lesions and arthritis: A case report

Xu XL, Liang XH, Liu J, Deng X, Zhang L, Wang ZG

- 7924** Brainstem abscesses caused by *Listeria monocytogenes*: A case report

Wang J, Li YC, Yang KY, Wang J, Dong Z

- 7931** Primary hypertension in a postoperative paraganglioma patient: A case report

Wei JH, Yan HL

- 7936** Long-term survival of gastric mixed neuroendocrine-non-neuroendocrine neoplasm: Two case reports

Woo LT, Ding YF, Mao CY, Qian J, Zhang XM, Xu N

- 7944** Percutaneous transforaminal endoscopic decompression combined with percutaneous vertebroplasty in treatment of lumbar vertebral body metastases: A case report

Ran Q, Li T, Kuang ZP, Guo XH

- 7950** Atypical imaging features of the primary spinal cord glioblastoma: A case report

Liang XY, Chen YP, Li Q, Zhou ZW

- 7960** Resection with limb salvage in an Asian male adolescent with Ewing's sarcoma: A case report

Lai CY, Chen KJ, Ho TY, Li LY, Kuo CC, Chen HT, Fong YC

- 7968** Early detection of circulating tumor DNA and successful treatment with osimertinib in thr790met-positive leptomeningeal metastatic lung cancer: A case report

Xu LQ, Wang YJ, Shen SL, Wu Y, Duan HZ

- 7973** Delayed arterial symptomatic epidural hematoma on the 14th day after posterior lumbar interbody fusion: A case report
Hao SS, Gao ZF, Li HK, Liu S, Dong SL, Chen HL, Zhang ZF
- 7982** Clinical and genetic analysis of nonketotic hyperglycinemia: A case report
Ning JJ, Li F, Li SQ
- 7989** Ectopic Cushing's syndrome in a patient with metastatic Merkel cell carcinoma: A case report
Ishay A, Touma E, Vornicova O, Dodiuk-Gad R, Goldman T, Bisharat N
- 7994** Occurrence of MYD88L265P and CD79B mutations in diffuse large b cell lymphoma with bone marrow infiltration: A case report
Huang WY, Weng ZY
- 8003** Rare case of compartment syndrome provoked by inhalation of polyurethane agent: A case report
Choi JH, Oh HM, Hwang JH, Kim KS, Lee SY
- 8009** Acute ischemic Stroke combined with Stanford type A aortic dissection: A case report and literature review
He ZY, Yao LP, Wang XK, Chen NY, Zhao JJ, Zhou Q, Yang XF
- 8018** Compound-honeysuckle-induced drug eruption with special manifestations: A case report
Zhou LF, Lu R
- 8025** Spontaneous internal carotid artery pseudoaneurysm complicated with ischemic stroke in a young man: A case report and review of literature
Zhong YL, Feng JP, Luo H, Gong XH, Wei ZH
- 8034** Microcystic adnexal carcinoma misdiagnosed as a "recurrent epidermal cyst": A case report
Yang SX, Mou Y, Wang S, Hu X, Li FQ
- 8040** Accidental discovery of appendiceal carcinoma during gynecological surgery: A case report
Wang L, Dong Y, Chen YH, Wang YN, Sun L
- 8045** Intra-ampullary papillary-tubular neoplasm combined with ampullary neuroendocrine carcinoma: A case report
Zavrtanik H, Luzar B, Tomažič A

LETTER TO THE EDITOR

- 8054** Commentary on "Primary orbital monophasic synovial sarcoma with calcification: A case report"
Tokur O, Aydin S, Karavas E

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Bennete Aloysius Fernandes, MDS, Professor, Faculty of Dentistry, SEGi University, Kota Damansara 47810, Selangor, Malaysia. drben17@yahoo.com

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJCC as 1.534; IF without journal self cites: 1.491; 5-year IF: 1.599; Journal Citation Indicator: 0.28; Ranking: 135 among 172 journals in medicine, general and internal; and Quartile category: Q4. The WJCC's CiteScore for 2021 is 1.2 and Scopus CiteScore rank 2021: General Medicine is 443/826.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Xu Guo*; Production Department Director: *Xiang Li*; Editorial Office Director: *Jin-Lei Wang*.

NAME OF JOURNAL

World Journal of Clinical Cases

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Thrice Monthly

EDITORS-IN-CHIEF

Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

PUBLICATION DATE

August 6, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Early detection of circulating tumor DNA and successful treatment with osimertinib in thr790met-positive leptomeningeal metastatic lung cancer: A case report

Li-Qing Xu, Ying-Jin Wang, Sheng-Li Shen, Yao Wu, Hong-Zhou Duan

Specialty type: Medicine, research and experimental

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): A, A
Grade B (Very good): B
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): E, E

P-Reviewer: Abdalla AN, Saudi Arabia; Kung WM, Taiwan; Sugimura H, Japan

Received: February 11, 2022

Peer-review started: February 11, 2022

First decision: May 30, 2022

Revised: June 2, 2022

Accepted: June 21, 2022

Article in press: June 21, 2022

Published online: August 6, 2022



Li-Qing Xu, Ying-Jin Wang, Sheng-Li Shen, Yao Wu, Hong-Zhou Duan, Department of Neurosurgery, Peking University First Hospital, Beijing 100034, China

Corresponding author: Hong-Zhou Duan, Doctor, PhD, Chief Doctor, Department of Neurosurgery, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China. duanhongzhou@126.com

Abstract

BACKGROUND

Patients diagnosed with non-small-cell lung cancer with activated epidermal growth factor receptor mutations are more likely to develop leptomeningeal (LM) metastasis than other types of lung cancers and have a poor prognosis. Early diagnosis and effective treatment of leptomeningeal carcinoma can improve the prognosis.

CASE SUMMARY

A 55-year-old female with a progressive headache and vomiting for one month was admitted to Peking University First Hospital. She was diagnosed with lung adenocarcinoma with osseous metastasis 10 months prior to admittance. epidermal growth factor receptor (EGFR) mutation was detected by genomic examination, so she was first treated with gefitinib for 10 months before acquiring resistance. Cell-free cerebrospinal fluid (CSF) circulating tumor DNA detection by next-generation sequencing was conducted and indicated the EGFR-Thr790Met mutation, while biopsy and cytology from the patient's CSF and the first enhanced cranial magnetic resonance imaging (MRI) showed no positive findings. A month later, the enhanced MRI showed linear leptomeningeal enhancement, and the cytology and biochemical examination in CSF remained negative. Therefore, osimertinib (80 mg/d) was initiated as a second-line treatment, resulting in a good response within a month.

CONCLUSION

This report suggests clinical benefit of osimertinib in LM patients with positive detection of the EGFR-Thr790Met mutation in CSF and proposes that the positive findings of CSF circulating tumor DNA as a liquid biopsy technology based on the detection of cancer-associated gene mutations may appear earlier than the imaging and CSF findings and may thus be helpful for therapy. Moreover, the

routine screening of chest CT with the novel coronavirus may provide unexpected benefits.

Key Words: Non-small cell lung cancer; Epidermal growth factor receptor mutation; Circulating tumor DNA detection; Leptomeningeal carcinomatosis; Osimertinib; Case report

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Examination of circulating tumor DNA in cell-free cerebrospinal fluid (CSF) has been shown to be useful for detecting the genomic mutations of tumors in the central nervous system, and osimertinib is considered to be a recent standardized treatment for epidermal growth factor receptor (EGFR) Thr790Met-mutant non-small-cell lung cancer (NSCLC). Hence, we report a patient with EGFR Thr790Met-mutant NSCLC with meningeal carcinomatosis and resistance to gefitinib and propose that the positive findings of CSF circulating tumor DNA as a liquid biopsy technology based on the detection of cancer-associated gene mutations that may appear earlier than the imaging and CSF findings and thus be helpful for therapy.

Citation: Xu LQ, Wang YJ, Shen SL, Wu Y, Duan HZ. Early detection of circulating tumor DNA and successful treatment with osimertinib in thr790met-positive leptomeningeal metastatic lung cancer: A case report. *World J Clin Cases* 2022; 10(22): 7968-7972

URL: <https://www.wjgnet.com/2307-8960/full/v10/i22/7968.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v10.i22.7968>

INTRODUCTION

Patients diagnosed with non-small-cell lung cancer (NSCLC) with activated epidermal growth factor receptor (EGFR) mutations are more apt to develop leptomeningeal (LM) metastasis than other types of lung cancers[1]. According to previous studies, patients with NSCLC with LM carcinoma have a poor prognosis[2]. Early diagnosis and effective treatment of LM carcinoma can improve the prognosis. Circulating tumor DNA (ctDNA) is composed of short, double-stranded DNA fragments from tumor cells. Examination of ctDNA in cell-free cerebrospinal fluid (CSF) has been shown to be useful in detecting the genomic mutations of tumors in the central nervous system (CNS) and has also been used to monitor tumor progression and evaluate the response to treatments[3-5]. However, it is unclear whether ctDNA detection in CSF can provide valuable clinical guidance for the treatment of meningeal metastases. Molecular targeted drugs such as EGFR tyrosine kinase inhibitors (TKIs) have been shown to be effective for patients with NSCLC and LM carcinoma who carry target oncogenes[6]. Osimertinib, a third-generation EGFR TKI, is considered to be a recent standardized treatment for EGFR Thr790Met-mutant NSCLC because of its good efficacy in both systemic and CNS metastasis[7]. However, relevant information about the effectiveness of osimertinib in EGFR Thr790Met-mutant meningeal carcinomatosis is limited. Here, we report a case of patient with EGFR Thr790Met-mutant NSCLC with meningeal carcinomatosis, which is resistant to gefitinib.


CASE PRESENTATION

Chief complaints

A 55-year-old female experiencing a progressive headache and vomiting for one month was admitted to our hospital.

History of present illness

55-year-old female experiencing a progressive headache and vomiting for one month was admitted to our hospital. She was diagnosed with lung adenocarcinoma (Figure 1A) with osseous metastasis 10 mo prior to admittance. EGFR mutation was detected upon genomic examination, so she was first treated with gefitinib for 10 mo before acquiring resistance. A previous enhanced cerebral magnetic resonance imaging (MRI) and PET-CT one month prior showed that there was no obvious abnormality in the CNS. Lumbar puncture showed an increased intracranial pressure (+ACY-gt+ADs-330 mmH₂O) without positive cytology and biochemical examination findings in the CSF. However, further CSF ctDNA detection by next-generation sequencing showed an EGFR-Thr790Met mutation. After the patient was admitted, a second enhanced MRI was performed and showed comprehensive linear leptomeningeal enhancement in the cerebral sulcus (Figure 1B). A second cytology and biochemical examination of the



DOI: 10.12998/wjcc.v10.i22.7968 Copyright ©The Author(s) 2022.

Figure 1 Chest computed tomography. A: Chest computed tomography image at admission shows a lesion in the lingual segment of the upper lobe of the left lung (arrows); B: A follow-up cerebral contrast-enhanced magnetic resonance imaging shows diffuse and linear enhancement along the surface of the cerebrum (arrows).

CSF remained negative.

History of past illness

The patient had no special history of past illness other than a hysterectomy procedure for fibroids 10 years prior.

Personal and family history

The patient had no special history of past illness other than a hysterectomy procedure for fibroids 10 years prior.

Physical examination

Neurological and pulmonary examination of the patient showed no obvious abnormalities.

Laboratory examinations

Lumbar puncture showed an increased intracranial pressure (> 330 mmH₂O) without positive cytology and biochemical examination findings in CSF. However, further CSF ctDNA detection by next-generation sequencing showed an EGFR-Thr790Met mutation, and the variation frequency was 11.7%.

Imaging examinations

(1) Chest CT image at admission shows a lesion in the lingual segment of the upper lobe of the left lung (arrows); and (2) A follow-up cerebral contrast-enhanced MRI shows diffuse and linear enhancement along the surface of the cerebrum (arrows).

FINAL DIAGNOSIS

Based on these findings, a diagnosis of LM carcinomatosis of EGFR-Thr790Met-positive lung adenocarcinoma (cT3N3M1b: stage IVA) was established.

TREATMENT

Neither surgery nor chemotherapy was applied to the patient due to osseous metastasis. In addition, surgery could not achieve a radical cure. Hence, osimertinib (80 mg/d) was given as a second-line treatment.

OUTCOME AND FOLLOW-UP

The patient showed a good response within a month. What's more, the patient's headache and symptoms of intracranial hypertension disappeared rapidly after 3 days of osimertinib treatment. After discharge, osimertinib (80 mg/d) was continued, and the patient was closely followed-up. There were no obvious toxic or adverse side effects except for diarrhea and leukopenia. The lung lesion continued to

shrink by the 6-month follow-up CT, and the intracranial pressure returned to normal without the patient experiencing a headache.

DISCUSSION

Patients with NSCLC and LM carcinoma have a poor prognosis. Early diagnosis and an appropriate treatment regimen are important to improve the prognosis. The analysis of ctDNA in CSF can be used to detect nervous system tumors and their drug resistance mechanism[8]. According to previous studies, EGFR-TKIs are effective in patients diagnosed with NSCLC and LM carcinoma with positive EGFR mutations[9]. Osimertinib has been reported to be more effective due to its better blood-brain barrier permeability[7]. This report shows a great clinical benefit of osimertinib in LM patients with positive detection of the EGFR-Thr790Met mutation in their CSF. Interestingly, the cytology in CSF and neuroimaging were all negative at the beginning, and when the patient's imaging turned positive, the result of CSF cytology examination was still negative one month after the EGFR-Thr790Met mutation was detected in CSF. Hence, we propose that the positive findings of CSF ctDNA as a liquid biopsy technology based on the detection of cancer-associated gene mutations may appear earlier than the imaging findings and the CSF findings and could thus be more helpful for therapy. Moreover, the character of this report is that headache is the chief complaint of the patient with lung cancer. The patient's initial outpatient cranial MRI and lumbar puncture showed no abnormalities in CSF biochemistry and cytology, except for elevated intracranial pressure. The patient's lung lesion was found due to the routine screening of chest CT with novel coronavirus. Just as the old saying goes, 'there is no great loss without some small gain'.

CONCLUSION

This report shows a great clinical benefit of osimertinib in LM patients with positive detection of the EGFR-Thr790Met mutation in CSF and proposes that the positive findings of CSF circulating tumor DNA as a liquid biopsy technology based on the detection of cancer-associated gene mutations may appear earlier than the imaging findings, and the CSF findings and could thus be helpful for therapy. Moreover, the routine screening of chest CT with the novel coronavirus may provide unexpected results.

FOOTNOTES

Author contributions: Xu LQ conceived the article; Xu LQ and Wang YJ collected the data; Wang YJ assembled the data; Xu LQ, Wang YJ, Shen SL, Wu Y and Duan HZ provided the study materials, write the manuscript and approved the manuscript.

Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images in October 20, 2021.

Conflict-of-interest statement: All authors declare that they have no conflict of interest to disclose.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Li-Qing Xu 0000-0003-4781-1882; Ying-Jin Wang 0000-0002-9166-0009; Sheng-Li Shen 0000-0003-4250-8577; Yao Wu 0000-0003-2697-3444; Hong-Zhou Duan 0000-0002-6456-2307.

S-Editor: Wang LL

L-Editor: A

P-Editor: Wang LL

REFERENCES

- 1 **Mok TS**, Wu Y-L, Ahn M-J, et al Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. *N Engl J Med* 2017; 376: 629-640 [PMID: [27959700](#) DOI: [10.1056/NEJMoa1612674](#)]
- 2 **Umemura S**, Tsubouchi K, Yoshioka H, Hotta K, Takigawa N, Fujiwara K, Horita N, Segawa Y, Hamada N, Takata I, Yamane H, Kamei H, Kiura K, Tanimoto M. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. *Lung Cancer* 2012; 77: 134-139 [PMID: [22487432](#) DOI: [10.1016/j.lungcan.2012.03.002](#)]
- 3 **De Mattos-Arruda L**, Mayor R, Ng CKY, Weigelt B, Martínez-Ricarte F, Torrejon D, Oliveira M, Arias A, Raventos C, Tang J, Guerini-Rocco E, Martínez-Sáez E, Lois S, Marín O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Ramon y Cajal S, Carles J, Rodon J, González-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. *Nat Commun* 2015; 6: 8839 [PMID: [26554728](#) DOI: [10.1038/ncomms9839](#)]
- 4 **Zhao Y**, He JY, Zou YL, Guo XS, Cui JZ, Guo L, Bu H. Evaluating the cerebrospinal fluid ctDNA detection by next-generation sequencing in the diagnosis of meningeal Carcinomatosis. *BMC Neurol* 2019; 19: 331 [PMID: [31856745](#) DOI: [10.1186/s12883-019-1554-5](#)]
- 5 **De Mattos-Arruda L**, Weigelt B, Cortes J, Won HH, Ng CKY, Nuciforo P, Bidard FC, Aura C, Saura C, Peg V, Piscuoglio S, Oliveira M, Smolders Y, Patel P, Norton L, Tabernero J, Berger MF, Seoane J, Reis-Filho JS. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. *Ann Oncol* 2014; 25: 1729-1735 [PMID: [25009010](#) DOI: [10.1093/annonc/mdx804](#)]
- 6 **Cheng H**, Perez-Soler R. Leptomeningeal metastases in non-small-cell lung cancer. *Lancet Oncol* 2018; 19: e43-e55 [PMID: [29304362](#) DOI: [10.1016/S1470-2045\(17\)30689-7](#)]
- 7 **Yang JCH**, Kim SW, Kim DW, Lee JS, Cho BC, Ahn JS, Lee DH, Kim TM, Goldman JW, Natale RB, Brown AP, Collins B, Chmielecki J, Vishwanathan K, Mendoza-Naranjo A, Ahn MJ. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. *J Clin Oncol* 2020; 38: 538-547 [PMID: [31809241](#) DOI: [10.1200/JCO.19.00457](#)]
- 8 **Zavodna M**, Bagshaw A, Brauning R, Gemmell NJ. The accuracy, feasibility and challenges of sequencing short tandem repeats using next-generation sequencing platforms. *PLoS One* 2014; 9: e113862 [PMID: [25436869](#) DOI: [10.1371/journal.pone.0113862](#)]
- 9 **Saboundji K**, Auliac JB, Pérol M, François G, Janicot H, Marcq M, Dubos-Arvis C, Renault A, Guisier F, Odier L, Gervais R, Chouaïd C. Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors. *Target Oncol* 2018; 13: 501-507 [PMID: [30039345](#) DOI: [10.1007/s11523-018-0581-2](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

